(NYSEMKT: STXS) Stereotaxis's forecast annual revenue growth rate of 23.02% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.58%.
Stereotaxis's revenue in 2025 is $30,074,000.On average, 6 Wall Street analysts forecast STXS's revenue for 2025 to be $3,127,032,834, with the lowest STXS revenue forecast at $2,990,685,355, and the highest STXS revenue forecast at $3,233,703,038. On average, 6 Wall Street analysts forecast STXS's revenue for 2026 to be $4,064,666,728, with the lowest STXS revenue forecast at $3,768,080,631, and the highest STXS revenue forecast at $4,360,599,551.
In 2027, STXS is forecast to generate $5,597,245,986 in revenue, with the lowest revenue forecast at $5,258,850,395 and the highest revenue forecast at $5,889,259,169.